A Phase 1/2 interventional study of satoreotide trizoxetan in Gastroenteropancreatic Neuroendocrine Tumors, sponsored by Ipsen. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-02.
Sponsored by Ipsen · Phase 1/2, Interventional, and Diagnostic
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
676 studies on the registry are indexed under Neuroendocrine Tumors; 169 are open to participants now.
This study's enrollment of 12 is below the median of 42 across 464 interventional studies indexed under Neuroendocrine Tumors.
Browse Neuroendocrine Tumors studies →Ipsen is the lead sponsor of 282 studies on the registry; 16 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
Drug: satoreotide trizoxetan
Also known as: 68Ga-OPS202
Number of Participants Reported With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs)
An AE was defined as any untoward medical occurrence in a participant administered a IP and which does not necessarily have a causal relationship with this treatment. For this study, all AEs were regarded as 'treatment emergent', i.e., not seen before administration of the IP or, if already present before administration, worsened after start of administration. An SAE was defined as an event that led to death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect. An ADR was defined as an AE with probable, possible or unlikely relationship to the administration of 68Ga-OPS202.
Time frame: From start of IP administration to end of the study visit (approximately 28 to 36 days)
Number of Participants With Clinical Significant Abnormalities in Laboratory Parameters, Vital Signs, Cardiac Safety, Physical Examination, and Required Concomitant Medication
Laboratory assessments included hematology, blood biochemistry and urine analysis. Vital signs included systolic and diastolic blood pressure, heart rate and axillary body temperature. Cardiac safety was assessed by 12-lead ECGs and physical examination included general appearance, head, neck, eyes, ears, nose, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal, neurological, endocrine, lymphatic, dermatological, psychological/psychiatric, abdomen, and genitourinary body systems. All medications (including herbal products) taken from visit 1 (Day 0) to visit 3 (7-15 days after visit 2 (3-4 weeks after visit 1), end of the study) were recorded in the participant's case report form.
Time frame: From start of IP administration to end of the study visit (approximately 28 to 36 days)
Number of Malignant and Benign Lesions Detected for Session 1
At visit 1, after administration of 15 μg 68Ga-OPS202, a dynamic scan was performed in kidney region over first 30 minutes; static scans were performed from head to sub-inguinal region at 0.5, 1, 2 and 4 h post-injection. At visit 2, after administration of 50 μg 68Ga-OPS202, a static scan was performed from head to sub-inguinal region at 1 h post-injection. A previous somatostatin receptor scan had been performed within 6 months prior to Day 0. Lesions were classified into malignant and benign by readers. Lesion matching was performed between somatostatin receptor scan and 1 h-68Ga-OPS202 receptor scans at visit 1 and visit 2. Number of lesions for each organ/tissue and overall were calculated and absolute numbers reported. Two different read sessions were held to generate data sets for evaluation of target variables. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
Time frame: 6 months prior to Day 0; and 1 hour post-injection on Day 0 and Day 21
Percentage of Participants With Lesion-Associated 68Ga-OPS202 Binding
Tumor contrast in PET imaging was determined by qualitative visual analysis. 68Ga-OPS202 binding was present if at least one lesion, regardless of nature, was detected within respective tissue location. Percentages were based on number of participants with available scan at corresponding time point.
Time frame: At 0.5, 1, 2, and 4 hour post-injection on Day 0 and 1 hour post-injection on Day 21
Mean Maximum Standardized Uptake Value (SUVmax) of Malignant and Benign Lesions for Session 1
At visit 1, after administration of 15 μg 68Ga-OPS202, a dynamic scan was performed in kidney region over the first 30 minutes (0-0.5 h); static scans were performed from head to sub-inguinal region at 0.5, 1, 2 and 4 h post-injection. At visit 2, after administration of 50 μg 68Ga-OPS202, a static scan was performed from head to sub-inguinal region at 1 h post-injection. A previous somatostatin receptor scan had been performed within 6 months prior to Day 0. Lesions were classified into malignant and benign lesion by the readers according to their experience. Lesion matching was performed between the somatostatin receptor scan and the 1 h-68Ga-OPS202 receptor scans at visit 1 and visit 2. The mean SUVmax of lesions (mean of all identified lesions in the lymph node and liver) was summarized by nature of the lesions (malignant, benign). Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
Time frame: 6 months prior to Day 0; and 1 hour post-injection on Day 0 and Day 21
Mean SUVmax of Malignant and Benign Lesions for Session 2
The mean SUVmax of all identified lesions in the respective organ/tissue was determined. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
Time frame: At 0.5, 1, 2, and 4 hour post-injection on Day 0 and 1 hour post-injection on Day 21
Mean SUVmax of Reference Tissues (RT) Region of Interests (ROIs) for Session 1
Lesion matching was performed between somatostatin receptor scan and 1 h-68Ga-OPS202 receptor scans at visit 1 and visit 2. Mean SUVmax of all selected ROIs in corresponding RT was determined. Corresponding RTs were adjacent healthy regions (1 to 3 healthy regions were identified for each lesion), i.e. located in same organ and/or region as lesion. RTs were determined in tissue locations with malignant lesions only. ROIs were also selected in muscle tissue, which was used as an additional reference region. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
Time frame: 6 months prior to Day 0; and 1 hour post-injection on Day 0 and Day 21
Mean SUVmax of RT for Session 2
The mean SUVmax of all selected ROIs in the corresponding RT was determined. RTs were determined in tissue locations with malignant lesions only. ROIs were also selected in muscle tissue, which was used as an additional reference region. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
Time frame: At 0.5, 1, 2, and 4 hour post-injection on Day 0 and 1 hour post-injection on Day 21
Mean Tumor Contrast (3D-SUV-R) of Malignant Lesions Compared to Pre-dose Scans for Session 1
The tumor contrast, i.e. the SUV ratio for tumor (malignant lesion)-to-background (3D-SUV-R) of a single lesion was defined as: 3D-SUV-R = SUVmax of lesion / mean of SUVmax of corresponding RTs. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
Time frame: 6 months prior to Day 0; and 1 hour post-injection on Day 0 and Day 21
The 3D-SUV-R of Malignant Lesions for Session 2
The tumor contrast, i.e. the SUV ratio for 3D-SUV-R of a single lesion was defined as: 3D-SUV-R = SUVmax of lesion / mean of SUVmax of corresponding RTs. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
Time frame: At 0.5, 1, 2, and 4 hour post-injection on Day 0 and 1 hour post-injection on Day 21
Percent Change in 3D-SUV-R of Malignant Lesions
The tumor contrast, i.e. the SUV ratio for 3D-SUV-R of a single lesion was defined as: 3D-SUV-R = SUVmax of lesion / mean of SUVmax of corresponding RT. For percent change, 68Ga-OPS202 receptor scan is compared to previous somatostatin receptor scan.
Time frame: 6 months prior to Day 0; and 1 hour post-injection on Day 0 and Day 21
Number of Participants at Each Time Point With the Highest Observed Lesion Number Per Tissue Location
For determining a suitable time window for PET/CT with 68Ga-OPS202, the scans after administration of the 15 μg peptide dose were analyzed and the time point with the highest lesion number per tissue location and overall were determined. If the highest number of lesion was detected at more than one time point, the earliest time point was used.
Time frame: At 0.5, 1, 2, and 4 hour post-injection on Day 0
Number of Participants at Each Time Point With the Highest Mean 3D-SUV-R Tumor Value
The time point with the highest mean 3D-SUV-R per tissue location were determined. If the highest mean 3D-SUV-R was detected at more than one time point, the earliest time point was used.
Time frame: At 0.5, 1, 2, and 4 hour post-injection on Day 0
Best Diagnostic Scan Assessment
The assessment of every diagnostic 68Ga-OPS202 PET/CT scan of session 2 was rated by the reader from 1 to 5, where 1=worst diagnostic scan and 5=best diagnostic scan. Higher score indicates a better scan.
Time frame: At 0.5, 1, 2, and 4 hour post-injection on Day 0 and 1 hour post-injection on Day 21
This open-label, micro-dosing study with 2 sequentially ascending single peptide doses was conducted in a single study center in Switzerland between 23 June 2014 and 14 January 2015.
| Milestone | All Participants |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
An AE was defined as any untoward medical occurrence in a participant administered a IP and which does not necessarily have a causal relationship with this treatment. For this study, all AEs were regarded as 'treatment emergent', i.e., not seen before administration of the IP or, if already present before administration, worsened after start of administration. An SAE was defined as an event that led to death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect. An ADR was defined as an AE with probable, possible or unlikely relationship to the administration of 68Ga-OPS202.
| Participants | All Participants |
|---|---|
| Any AE | 6 |
| SAEs | 0 |
| ADRs | 5 |
Laboratory assessments included hematology, blood biochemistry and urine analysis. Vital signs included systolic and diastolic blood pressure, heart rate and axillary body temperature. Cardiac safety was assessed by 12-lead ECGs and physical examination included general appearance, head, neck, eyes, ears, nose, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal, neurological, endocrine, lymphatic, dermatological, psychological/psychiatric, abdomen, and genitourinary body systems. All medications (including herbal products) taken from visit 1 (Day 0) to visit 3 (7-15 days after visit 2 (3-4 weeks after visit 1), end of the study) were recorded in the participant's case report form.
| Participants | All Participants |
|---|---|
| Laboratory parameters abnormalities | 8 |
| Vital sign abnormalities | 7 |
| 12-Lead ECG abnormalities | 1 |
| Physical examination abnormalities | 9 |
| Concomitant medications required | 12 |
At visit 1, after administration of 15 μg 68Ga-OPS202, a dynamic scan was performed in kidney region over first 30 minutes; static scans were performed from head to sub-inguinal region at 0.5, 1, 2 and 4 h post-injection. At visit 2, after administration of 50 μg 68Ga-OPS202, a static scan was performed from head to sub-inguinal region at 1 h post-injection. A previous somatostatin receptor scan had been performed within 6 months prior to Day 0. Lesions were classified into malignant and benign by readers. Lesion matching was performed between somatostatin receptor scan and 1 h-68Ga-OPS202 receptor scans at visit 1 and visit 2. Number of lesions for each organ/tissue and overall were calculated and absolute numbers reported. Two different read sessions were held to generate data sets for evaluation of target variables. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
| lesion | ITT Population (Pre-dose) | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|---|
| Malignant: Total | 9.3 ± 10.49 | 17.0 ± 17.31 | 20.1 ± 20.58 |
| Malignant: Bone | 1.0 ± 0.00 | 1.0 ± 0.00 | 1.0 ± 0.00 |
| Malignant: Liver | 8.6 ± 10.62 | 17.4 ± 17.98 | 21.7 ± 20.86 |
| Malignant: Lymph node | 2.5 ± 2.56 | 2.9 ± 2.10 | 2.5 ± 2.27 |
| Malignant: Peritoneum | 1.0 ± NA | 1.0 ± NA | 1.0 ± NA |
| Malignant: Small bowel | 1.0 ± 0.00 | 2.0 ± 1.41 | 1.5 ± 0.71 |
| Benign: Total | 3.0 ± 1.83 | 1.8 ± 2.87 | 3.0 ± 3.16 |
| Benign: Lung | 0.0 ± NA | 2.0 ± NA | 3.0 ± NA |
| Benign: Lymph node | 1.0 ± NA | 0.0 ± NA | 0.0 ± NA |
| Benign: Mamma | 2.0 ± NA | 2.0 ± NA | 2.0 ± NA |
| Benign: Mediastinum | 1.0 ± NA | 0.0 ± NA | 0.0 ± NA |
| Benign: Pancreas | 1.0 ± NA | 1.0 ± NA | 1.0 ± NA |
| Benign: Small bowel | 4.0 ± NA | 0.0 ± NA | 4.0 ± NA |
| Benign: Spleen | 1.0 ± NA | 1.0 ± NA | 1.0 ± NA |
| Benign: Stomach | 1.0 ± NA | 1.0 ± NA | 1.0 ± NA |
| Benign: Thyroid gland | 1.0 ± NA | 0.0 ± NA | 0.0 ± NA |
Tumor contrast in PET imaging was determined by qualitative visual analysis. 68Ga-OPS202 binding was present if at least one lesion, regardless of nature, was detected within respective tissue location. Percentages were based on number of participants with available scan at corresponding time point.
| percentage of participants | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|
| Total: At 0.5 hour | 100 | — |
| Total: At 1 hour | 100 | 100 |
| Total: At 2 hour | 100 | — |
| Total: At 4 hour | 100 | — |
| Bone: At 0.5 hour | 16.7 | — |
| Bone: At 1 hour | 16.7 | 16.7 |
| Bone: At 2 hour | 16.7 | — |
| Bone: At 4 hour | 16.7 | — |
| Liver: At 0.5 hour | 75.0 | — |
| Liver: At 1 hour | 75.0 | 75.0 |
| Liver: At 2 hour | 75.0 | — |
| Liver: At 4 hour | 75.0 | — |
| Lung: At 0.5 hour | 0 | — |
| Lung: At 1 hour | 0 | 0 |
| Lung: At 2 hour | 0 | — |
| Lung: At 4 hour | 0 | — |
| Lymph node: At 0.5 hour | 58.3 | — |
| Lymph node: At 1 hour | 58.3 | 58.3 |
| Lymph node: At 2 hour | 58.3 | — |
| Lymph node: At 4 hour | 58.3 | — |
| Mamma: At 0.5 hour | 0 | — |
| Mamma: At 1 hour | 0 | 0 |
| Mamma: At 2 hour | 0 | — |
| Mamma: At 4 hour | 0 | — |
| Pancreas: At 0.5 hour | 8.3 | — |
| Pancreas: At 1 hour | 8.3 | 8.3 |
| Pancreas: At 2 hour | 8.3 | — |
| Pancreas: At 4 hour | 8.3 | — |
| Peritoneum: At 0.5 hour | 8.3 | — |
| Peritoneum: At 1 hour | 8.3 | 8.3 |
| Peritoneum: At 2 hour | 8.3 | — |
| Peritoneum: At 4 hour | 8.3 | — |
| Small bowel: At 0.5 hour | 25.0 | — |
| Small bowel: At 1 hour | 25.0 | 25.0 |
| Small bowel: At 2 hour | 25.0 | — |
| Small bowel: At 4 hour | 16.7 | — |
| Thyroid gland: At 0.5 hour | 0 | — |
| Thyroid gland: At 1 hour | 0 | 0 |
| Thyroid gland: At 2 hour | 0 | — |
| Thyroid gland: At 4 hour | 0 | — |
At visit 1, after administration of 15 μg 68Ga-OPS202, a dynamic scan was performed in kidney region over the first 30 minutes (0-0.5 h); static scans were performed from head to sub-inguinal region at 0.5, 1, 2 and 4 h post-injection. At visit 2, after administration of 50 μg 68Ga-OPS202, a static scan was performed from head to sub-inguinal region at 1 h post-injection. A previous somatostatin receptor scan had been performed within 6 months prior to Day 0. Lesions were classified into malignant and benign lesion by the readers according to their experience. Lesion matching was performed between the somatostatin receptor scan and the 1 h-68Ga-OPS202 receptor scans at visit 1 and visit 2. The mean SUVmax of lesions (mean of all identified lesions in the lymph node and liver) was summarized by nature of the lesions (malignant, benign). Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
| SUVmax | ITT Population (Pre-dose) | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|---|
| Malignant: Bone | 4.394 ± 0.9396 | 4.153 ± 2.0270 | 4.455 ± 0.2425 |
| Malignant: Liver | 12.135 ± 4.4660 | 10.468 ± 4.7970 | 8.458 ± 3.4840 |
| Malignant: Lymph node | 15.192 ± 7.4318 | 16.289 ± 12.0091 | 14.602 ± 10.9725 |
| Malignant: Peritoneum | 6.579 ± NA | 6.740 ± NA | 9.504 ± NA |
| Malignant: Small bowel | 14.049 ± 0.2124 | 11.140 ± 7.9828 | 9.156 ± 1.0674 |
| Benign: Lung | — | 3.410 ± NA | 3.131 ± NA |
| Benign: Lymph node | 3.093 ± NA | — | — |
| Benign: Mamma | 2.353 ± NA | 2.907 ± NA | 2.538 ± NA |
| Benign: Mediastinum | 2.242 ± NA | — | — |
| Benign: Pancreas | 14.086 ± NA | 8.693 ± NA | 6.659 ± NA |
| Benign: Small bowel | 8.264 ± NA | — | 4.990 ± NA |
| Benign: Spleen | 16.343 ± NA | 15.997 ± NA | 14.308 ± NA |
| Benign: Stomach | 6.713 ± NA | 7.630 ± NA | 5.305 ± NA |
| Benign: Thyroid gland | 3.768 ± NA | — | — |
The mean SUVmax of all identified lesions in the respective organ/tissue was determined. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
| SUVmax | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|
| Malignant: Bone: At 0.5 hour | 4.938 ± 1.1179 | — |
| Malignant: Bone: At 1 hour | 4.153 ± 2.0270 | 4.455 ± 0.2425 |
| Malignant: Bone: At 2 hour | 4.601 ± 1.3164 | — |
| Malignant: Bone: At 4 hour | 4.564 ± 1.0832 | — |
| Malignant: Liver: At 0.5 hour | 10.086 ± 5.0229 | — |
| Malignant: Liver: At 1 hour | 11.485 ± 6.3691 | 9.037 ± 3.9033 |
| Malignant: Liver: At 2 hour | 9.897 ± 4.3537 | — |
| Malignant: Liver: At 4 hour | 12.482 ± 5.9410 | — |
| Malignant: Lymph node: At 0.5 hour | 14.581 ± 9.7609 | — |
| Malignant: Lymph node: At 1 hour | 17.044 ± 11.6224 | 15.836 ± 10.9868 |
| Malignant: Lymph node: At 2 hour | 18.166 ± 10.6940 | — |
| Malignant: Lymph node: At 4 hour | 17.985 ± 13.5368 | — |
| Malignant: Peritoneum: At 0.5 hour | 3.293 ± NA | — |
| Malignant: Peritoneum: At 1 hour | 6.740 ± NA | 9.504 ± NA |
| Malignant: Peritoneum: At 2 hour | 7.484 ± NA | — |
| Malignant: Peritoneum: At 4 hour | 7.216 ± NA | — |
| Malignant: Small bowel: At 0.5 hour | 9.474 ± 5.8641 | — |
| Malignant: Small bowel: At 1 hour | 11.207 ± 4.5367 | 7.440 ± 2.8588 |
| Malignant: Small bowel: At 2 hour | 9.075 ± 4.9059 | — |
| Malignant: Small bowel: At 4 hour | 14.695 ± 6.9926 | — |
| Benign: Pancreas: At 0.5 hour | 8.561 ± NA | — |
| Benign: Pancreas: At 1 hour | 8.512 ± NA | 6.659 ± NA |
| Benign: Pancreas: At 2 hour | 8.734 ± NA | — |
| Benign: Pancreas: At 4 hour | 5.759 ± NA | — |
Lesion matching was performed between somatostatin receptor scan and 1 h-68Ga-OPS202 receptor scans at visit 1 and visit 2. Mean SUVmax of all selected ROIs in corresponding RT was determined. Corresponding RTs were adjacent healthy regions (1 to 3 healthy regions were identified for each lesion), i.e. located in same organ and/or region as lesion. RTs were determined in tissue locations with malignant lesions only. ROIs were also selected in muscle tissue, which was used as an additional reference region. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
| SUVmax | ITT Population (Pre-dose) | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|---|
| Bone | 0.610 ± 0.1801 | 0.739 ± 0.1780 | 0.636 ± 0.1207 |
| Muscle | 1.020 ± 0.3141 | 0.883 ± 0.2530 | 0.896 ± 0.1812 |
| Liver | 6.801 ± 1.9676 | 3.642 ± 1.6381 | 2.959 ± 0.8089 |
| Lymph node | 2.229 ± 1.2017 | 1.870 ± 0.6967 | 2.368 ± 1.7112 |
| Peritoneum | 0.776 ± NA | 0.927 ± NA | 1.401 ± NA |
| Small bowel | 4.180 ± 0.7893 | 2.080 ± 0.5162 | 1.707 ± 0.0636 |
The mean SUVmax of all selected ROIs in the corresponding RT was determined. RTs were determined in tissue locations with malignant lesions only. ROIs were also selected in muscle tissue, which was used as an additional reference region. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
| SUVmax | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|
| Muscle: At 0.5 hour | 0.923 ± 0.2260 | — |
| Muscle: At 1 hour | 0.932 ± 0.2386 | 0.976 ± 0.2012 |
| Muscle: At 2 hour | 1.127 ± 0.3343 | — |
| Muscle: At 4 hour | 2.013 ± 0.6884 | — |
| Bone: At 0.5 hour | 0.573 ± 0.3418 | — |
| Bone: At 1 hour | 0.605 ± 0.3681 | 0.765 ± 0.1409 |
| Bone: At 2 hour | 0.731 ± 0.0550 | — |
| Bone: At 4 hour | 2.138 ± 0.7022 | — |
| Liver: At 0.5 hour | 4.201 ± 1.3697 | — |
| Liver: At 1 hour | 4.040 ± 1.5213 | 3.480 ± 1.1863 |
| Liver: At 2 hour | 4.103 ± 1.2389 | — |
| Liver: At 4 hour | 6.101 ± 2.7773 | — |
| Lymph node: At 0.5 hour | 1.723 ± 0.9118 | — |
| Lymph node: At 1 hour | 2.049 ± 0.7805 | 1.757 ± 1.1486 |
| Lymph node: At 2 hour | 2.467 ± 1.3033 | — |
| Lymph node: At 4 hour | 1.989 ± 0.6904 | — |
| Peritoneum: At 0.5 hour | 1.864 ± NA | — |
| Peritoneum: At 1 hour | 1.038 ± NA | 1.163 ± NA |
| Peritoneum: At 2 hour | 0.856 ± NA | — |
| Peritoneum: At 4 hour | 1.501 ± NA | — |
| Small bowel: At 0.5 hour | 2.519 ± 0.2743 | — |
| Small bowel: At 1 hour | 2.571 ± 1.0644 | 1.608 ± 0.3677 |
| Small bowel: At 2 hour | 2.124 ± 0.7382 | — |
| Small bowel: At 4 hour | 3.177 ± 0.7174 | — |
The tumor contrast, i.e. the SUV ratio for tumor (malignant lesion)-to-background (3D-SUV-R) of a single lesion was defined as: 3D-SUV-R = SUVmax of lesion / mean of SUVmax of corresponding RTs. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
| ratio | ITT Population (Pre-dose) | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|---|
| Bone (RT: Bone) | 7.296 ± 0.6136 | 6.125 ± 4.2161 | 7.167 ± 1.7409 |
| Bone (RT: Muscle) | 5.227 ± 1.7044 | 6.091 ± 2.1353 | 5.868 ± 0.4515 |
| Liver (RT: Liver) | 2.066 ± 0.9163 | 3.234 ± 1.8130 | 3.215 ± 1.8160 |
| Liver (RT: Muscle) | 13.434 ± 7.3703 | 12.605 ± 7.9383 | 10.318 ± 5.7811 |
| Lymph node (RT: Lymph node) | 9.548 ± 7.1592 | 9.320 ± 5.2590 | 11.034 ± 13.3938 |
| Lymph node (RT: Muscle) | 15.110 ± 7.4282 | 19.861 ± 16.0492 | 18.349 ± 15.9027 |
| Peritoneum (RT: Peritoneum) | 8.475 ± NA | 7.268 ± NA | 6.783 ± NA |
| Peritoneum (RT: Muscle) | 8.366 ± NA | 9.170 ± NA | 11.399 ± NA |
| Small bowel (RT: Small bowel) | 3.427 ± 0.6978 | 6.017 ± 5.3303 | 5.355 ± 0.4256 |
| Small bowel (RT: Muscle) | 15.353 ± 7.1430 | 12.585 ± 6.1981 | 11.352 ± 2.5753 |
The tumor contrast, i.e. the SUV ratio for 3D-SUV-R of a single lesion was defined as: 3D-SUV-R = SUVmax of lesion / mean of SUVmax of corresponding RTs. Statistical comparisons were only feasible for those organs/ tissues that had sufficient participants with lesions detected.
| ratio | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|
| Bone (RT: Bone): At 0.5 hour | 11.191 ± 8.6266 | — |
| Bone (RT: Bone): At 1 hour | 9.679 ± 9.2426 | 5.891 ± 0.7682 |
| Bone (RT: Bone): At 2 hour | 6.243 ± 1.3313 | — |
| Bone (RT: Bone): At 4 hour | 2.169 ± 0.2056 | — |
| Bone (RT: Muscle): At 0.5 hour | 6.716 ± 1.4013 | — |
| Bone (RT: Muscle): At 1 hour | 5.528 ± 2.1555 | 5.530 ± 0.8944 |
| Bone (RT: Muscle): At 2 hour | 5.311 ± 2.1658 | — |
| Bone (RT: Muscle): At 4 hour | 2.331 ± 0.5535 | — |
| Liver (RT: Liver): At 0.5 hour | 2.547 ± 1.5468 | — |
| Liver (RT: Liver): At 1 hour | 3.071 ± 2.3858 | 2.514 ± 0.6087 |
| Liver (RT: Liver): At 2 hour | 2.430 ± 0.9559 | — |
| Liver (RT: Liver): At 4 hour | 2.038 ± 0.6822 | — |
| Liver (RT: Muscle): At 0.5 hour | 11.534 ± 8.0671 | — |
| Liver (RT: Muscle): At 1 hour | 13.231 ± 10.4892 | 9.653 ± 5.1879 |
| Liver (RT: Muscle): At 2 hour | 9.383 ± 6.1356 | — |
| Liver (RT: Muscle): At 4 hour | 6.974 ± 6.4729 | — |
| Lymph node (RT: Lymph node): At 0.5 hour | 13.448 ± 12.3973 | — |
| Lymph node (RT: Lymph node): At 1 hour | 10.109 ± 7.3722 | 14.166 ± 13.4067 |
| Lymph node (RT: Lymph node): At 2 hour | 9.722 ± 7.1821 | — |
| Lymph node (RT: Lymph node): At 4 hour | 9.889 ± 5.8842 | — |
| Lymph node (RT: Muscle): At 0.5 hour | 16.362 ± 9.1362 | — |
| Lymph node (RT: Muscle): At 1 hour | 20.434 ± 13.6060 | 18.562 ± 15.1302 |
| Lymph node (RT: Muscle): At 2 hour | 16.107 ± 9.5271 | — |
| Lymph node (RT: Muscle): At 4 hour | 8.619 ± 3.7444 | — |
| Peritoneum (RT: Peritoneum): At 0.5 hour | 1.767 ± NA | — |
| Peritoneum (RT: Peritoneum): At 1 hour | 6.494 ± NA | 8.173 ± NA |
| Peritoneum (RT: Peritoneum): At 2 hour | 8.747 ± NA | — |
| Peritoneum (RT: Peritoneum): At 4 hour | 4.809 ± NA | — |
| Peritoneum (RT: Muscle): At 0.5 hour | 4.431 ± NA | — |
| Peritoneum (RT: Muscle): At 1 hour | 8.508 ± NA | 10.060 ± NA |
| Peritoneum (RT: Muscle): At 2 hour | 7.709 ± NA | — |
| Peritoneum (RT: Muscle): At 4 hour | 2.626 ± NA | — |
| Small bowel (RT: Small bowel): At 0.5 hour | 3.759 ± 2.1690 | — |
| Small bowel (RT: Small bowel): At 1 hour | 5.644 ± 4.9619 | 4.956 ± 2.8311 |
| Small bowel (RT: Small bowel): At 2 hour | 4.363 ± 2.5614 | — |
| Small bowel (RT: Small bowel): At 4 hour | 4.047 ± 1.6457 | — |
| Small bowel (RT: Muscle): At 0.5 hour | 9.404 ± 5.2820 | — |
| Small bowel (RT: Muscle): At 1 hour | 11.787 ± 5.8090 | 7.678 ± 3.9023 |
| Small bowel (RT: Muscle): At 2 hour | 7.267 ± 3.8995 | — |
| Small bowel (RT: Muscle): At 4 hour | 6.686 ± 1.5046 | — |
The tumor contrast, i.e. the SUV ratio for 3D-SUV-R of a single lesion was defined as: 3D-SUV-R = SUVmax of lesion / mean of SUVmax of corresponding RT. For percent change, 68Ga-OPS202 receptor scan is compared to previous somatostatin receptor scan.
| percent change | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|
| Bone (RT: Bone) | -13.315 ± 65.0759 | -0.418 ± 32.2352 |
| Bone (RT: Muscle) | 16.042 ± 3.0132 | 20.052 ± 47.7825 |
| Liver (RT: Liver) | 51.938 ± 33.2221 | 50.766 ± 25.4179 |
| Liver (RT: Muscle) | -5.165 ± 32.3975 | -19.838 ± 37.5669 |
| Lymph node (RT: Lymph node) | 56.044 ± 94.8768 | 38.530 ± 117.3139 |
| Lymph node (RT: Muscle) | 46.569 ± 61.4515 | 36.864 ± 79.3287 |
| Peritoneum (RT: Peritoneum) | -14.239 ± NA | -19.962 ± NA |
| Peritoneum (RT: Muscle) | 9.619 ± NA | 36.256 ± NA |
| Small bowel (RT: Small bowel) | 63.131 ± 122.3379 | 58.296 ± 19.8143 |
| Small bowel (RT: Muscle) | 2.447 ± 88.0324 | -12.716 ± 57.3817 |
For determining a suitable time window for PET/CT with 68Ga-OPS202, the scans after administration of the 15 μg peptide dose were analyzed and the time point with the highest lesion number per tissue location and overall were determined. If the highest number of lesion was detected at more than one time point, the earliest time point was used.
| Participants | ITT Population (Day 0) |
|---|---|
| Total — At 0.5 hour | 5 |
| Total — At 1 hour | 3 |
| Total — At 2 hour | 4 |
| Total — At 4 hour | 0 |
| Bone — At 0.5 hour | 2 |
| Bone — At 1 hour | 0 |
| Bone — At 2 hour | 0 |
| Bone — At 4 hour | 0 |
| Liver — At 0.5 hour | 2 |
| Liver — At 1 hour | 3 |
| Liver — At 2 hour | 4 |
| Liver — At 4 hour | 0 |
| Lung — At 0.5 hour | — |
| Lung — At 1 hour | — |
| Lung — At 2 hour | — |
| Lung — At 4 hour | — |
| Lymph node — At 0.5 hour | 7 |
| Lymph node — At 1 hour | 0 |
| Lymph node — At 2 hour | 0 |
| Lymph node — At 4 hour | 0 |
| Mamma — At 0.5 hour | — |
| Mamma — At 1 hour | — |
| Mamma — At 2 hour | — |
| Mamma — At 4 hour | — |
| Pancreas — At 0.5 hour | 1 |
| Pancreas — At 1 hour | 0 |
| Pancreas — At 2 hour | 0 |
| Pancreas — At 4 hour | 0 |
| Peritoneum — At 0.5 hour | 1 |
| Peritoneum — At 1 hour | 0 |
| Peritoneum — At 2 hour | 0 |
| Peritoneum — At 4 hour | 0 |
| Small bowel — At 0.5 hour | 3 |
| Small bowel — At 1 hour | 0 |
| Small bowel — At 2 hour | 0 |
| Small bowel — At 4 hour | 0 |
| Thyroid gland — At 0.5 hour | — |
| Thyroid gland — At 1 hour | — |
| Thyroid gland — At 2 hour | — |
| Thyroid gland — At 4 hour | — |
The time point with the highest mean 3D-SUV-R per tissue location were determined. If the highest mean 3D-SUV-R was detected at more than one time point, the earliest time point was used.
| Participants | ITT Population (Day 0) |
|---|---|
| Bone (RT: Bone) — At 0.5 hour | 1 |
| Bone (RT: Bone) — At 1 hour | 0 |
| Bone (RT: Bone) — At 2 hour | 1 |
| Bone (RT: Bone) — At 4 hour | 0 |
| Bone (RT: Muscle) — At 0.5 hour | 1 |
| Bone (RT: Muscle) — At 1 hour | 0 |
| Bone (RT: Muscle) — At 2 hour | 1 |
| Bone (RT: Muscle) — At 4 hour | 0 |
| Liver (RT: Liver) — At 0.5 hour | 0 |
| Liver (RT: Liver) — At 1 hour | 4 |
| Liver (RT: Liver) — At 2 hour | 2 |
| Liver (RT: Liver) — At 4 hour | 3 |
| Liver (RT: Muscle) — At 0.5 hour | 2 |
| Liver (RT: Muscle) — At 1 hour | 5 |
| Liver (RT: Muscle) — At 2 hour | 2 |
| Liver (RT: Muscle) — At 4 hour | 0 |
| Lymph node (RT: Lymph node) — At 0.5 hour | 2 |
| Lymph node (RT: Lymph node) — At 1 hour | 1 |
| Lymph node (RT: Lymph node) — At 2 hour | 2 |
| Lymph node (RT: Lymph node) — At 4 hour | 2 |
| Lymph node (RT: Muscle) — At 0.5 hour | 1 |
| Lymph node (RT: Muscle) — At 1 hour | 5 |
| Lymph node (RT: Muscle) — At 2 hour | 1 |
| Lymph node (RT: Muscle) — At 4 hour | 0 |
| Mamma (RT: Mamma) — At 0.5 hour | — |
| Mamma (RT: Mamma) — At 1 hour | — |
| Mamma (RT: Mamma) — At 2 hour | — |
| Mamma (RT: Mamma) — At 4 hour | — |
| Mamma (RT: Muscle) — At 0.5 hour | — |
| Mamma (RT: Muscle) — At 1 hour | — |
| Mamma (RT: Muscle) — At 2 hour | — |
| Mamma (RT: Muscle) — At 4 hour | — |
| Peritoneum (RT: Peritoneum) — At 0.5 hour | 0 |
| Peritoneum (RT: Peritoneum) — At 1 hour | 0 |
| Peritoneum (RT: Peritoneum) — At 2 hour | 1 |
| Peritoneum (RT: Peritoneum) — At 4 hour | 0 |
| Peritoneum (RT: Muscle) — At 0.5 hour | 0 |
| Peritoneum (RT: Muscle) — At 1 hour | 1 |
| Peritoneum (RT: Muscle) — At 2 hour | 0 |
| Peritoneum (RT: Muscle) — At 4 hour | 0 |
| Small bowel (RT: Small bowel) — At 0.5 hour | 1 |
| Small bowel (RT: Small bowel) — At 1 hour | 2 |
| Small bowel (RT: Small bowel) — At 2 hour | 0 |
| Small bowel (RT: Small bowel) — At 4 hour | 0 |
| Small bowel (RT: Muscle) — At 0.5 hour | 0 |
| Small bowel (RT: Muscle) — At 1 hour | 3 |
| Small bowel (RT: Muscle) — At 2 hour | 0 |
| Small bowel (RT: Muscle) — At 4 hour | 0 |
The assessment of every diagnostic 68Ga-OPS202 PET/CT scan of session 2 was rated by the reader from 1 to 5, where 1=worst diagnostic scan and 5=best diagnostic scan. Higher score indicates a better scan.
| score on a scale | ITT Population (Day 0) | ITT Population (Day 21) |
|---|---|---|
| At 0.5 hour | 4.0 (2 to 5) | — |
| At 1 hour | 5.0 (3 to 5) | 5.0 (3 to 5) |
| At 2 hour | 4.5 (3 to 5) | — |
| At 4 hour | 2.0 (1 to 4) | — |
Collected over From start of IP administration to end of the study visit (approximately 28 to 36 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Event | All Participants |
|---|---|
| Urinary tract infectionInfections and infestations | 2/12 |
| FatigueGeneral disorders | 2/12 |
| NasopharyngitisInfections and infestations | 1/12 |
| Abdominal pain upperGastrointestinal disorders | 1/12 |
| DiarrhoeaGastrointestinal disorders | 1/12 |
| EosinophiliaBlood and lymphatic system disorders | 1/12 |
| Liver function test abnormalInvestigations | 1/12 |
| HeadacheNervous system disorders | 1/12 |
| RashSkin and subcutaneous tissue disorders | 1/12 |
Safety analysis set (SAF) included all participants of the full analysis set (FAS) who received the IP, regardless of any protocol deviations.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 54.8 ± 14.66 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 5 |
| Male | 7 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 11 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ipsen